Ho, CLB and Breslin, M and Chowdhury, EK and Doust, J and Reid, CM and Davis, BR and Simpson, LM and Nelson, MR, Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, Journal of Hypertension, 37, (1) pp. 1-8. ISSN 0263-6352 (2019) [Refereed Article]
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Methods: A post-hoc observational study of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. We excluded participants with a previous history of CVD events. Cox proportional hazard model and 95% confidence interval were used to estimate the effects of treatment naive on mortality outcomes. Moreover, a subgroup analysis by estimated 10-year Framingham risk score was performed.
Results: In multivariable models adjusting for baseline and in-trial characteristics (BP values and number of BP medications as time-dependent variables), there was no statistically significant difference in 5 and 14-year all-cause mortality with a hazard ratio of 0.93 (95% confidence interval 0.80-1.09) and hazard ratio 0.95 (0.88-1.03) and in 5 and 14-year CVD mortality hazard ratio 0.94 (0.72-1.23) and hazard ratio 0.93 (0.80-1.08). In subgroup by absolute CVD risk, no heterogeneity of the association between treatment naive and short-term or long-term all-cause or CVD mortality were found. All comparisons are between the treatment-naive and previous treatment groups.
Conclusion: Physicians are concerned about 'legacy effects' of not treating individuals with a BP of 140 mmHg or over and low absolute risk. When treatment intensification was taken into consideration in the primary prevention population in this study, no adverse legacy effect as a result of baseline BP 'treatment naivety' was evident in 14 years of follow-up. The nonsignificant associations were consistent across the CVD risk subgroups. However, the results may be biased due to unobserved residual confounding and therefore should be interpreted with caution.
|Item Type:||Refereed Article|
|Keywords:||absolute cardiovascular risk, all-cause mortality, antihypertensive drug, cardiovascular disease, cardiovascular disease mortality, hypertension, primary prevention, blood pressure lowering drug therapy|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Cardiovascular medicine and haematology|
|Research Field:||Cardiology (incl. cardiovascular diseases)|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Ho, CLB (Ms Chau Le Bao Ho)|
|UTAS Author:||Breslin, M (Dr Monique Breslin)|
|UTAS Author:||Nelson, MR (Professor Mark Nelson)|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page